Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
Alzheimer Disease and Associated Disorders|December 28, 1999
Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study GroupB KittnerEuropean Journal of Pharmacology|August 7, 1986
Apomorphine does not decrease tissue levels of tetrahydrobiopterin in vivoM Bräutigam, B Kittner, H HerkenNaunyn-Schmiedeberg'S Archives of Pharmacology|April 1, 1986
Direct inhibition of tyrosine hydroxylase from PC-12 cells by catechol derivativesG Laschinski, B Kittner, M BräutigamMolecular Pharmacology|December 1, 1985
Effects of apomorphine enantiomers and of lisuride on 3,4-dihydroxyphenylalanine production in striatal synaptosomesM Bräutigam, B Kittner, G LaschinskiAnnals of the New York Academy of Sciences|November 5, 1997
Clinical trials in dementia with propentofyllineB Kittner, M Rössner, M RotherArzneimittel-Forschung|January 1, 1985
Evaluation of neurotropic drug actions on tyrosine hydroxylase activity and dopamine metabolism in clonal cell linesM Bräutigam, B Kittner, H HerkenNaunyn-Schmiedeberg'S Archives of Pharmacology|September 1, 1984
Inhibition of striatal tyrosine hydroxylase by low concentrations of apomorphineG Laschinski, B Kittner, M BräutigamArchives Internationales De Pharmacodynamie Et De Therapie|April 1, 1987
PC12 cells: a model system for studying drug effects on dopamine synthesis and releaseB Kittner, M Bräutigam, H HerkenBiochemical Pharmacology|April 1, 1985
Effect of apomorphine, alpha-methylparatyrosine, haloperidol and reserpine on DOPA production in clonal cell lines (PC-12 and N1E-115)M Bräutigam, G Laschinski, B Kittner, et al.Annals of the New York Academy of Sciences|January 17, 1996
HWA 285 (propentofylline)--a new compound for the treatment of both vascular dementia and dementia of the Alzheimer typeM Rother, B Kittner, K Rudolphi, et al.Pageof 2